Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304


CD151 Expression Is Associated with a Hyperproliferative T Cell Phenotype.

Seu L, Tidwell C, Timares L, Duverger A, Wagner FH, Goepfert PA, Westfall AO, Sabbaj S, Kutsch O.

J Immunol. 2017 Nov 1;199(9):3336-3347. doi: 10.4049/jimmunol.1700648. Epub 2017 Sep 27.


Human Articular Chondrocytes Induce Interleukin-2 Nonresponsiveness to Allogeneic Lymphocytes.

Abe S, Nochi H, Ito H.

Cartilage. 2017 Jul;8(3):300-306. doi: 10.1177/1947603516661820. Epub 2016 Aug 2.


Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.

Vazquez-Lombardi R, Loetsch C, Zinkl D, Jackson J, Schofield P, Deenick EK, King C, Phan TG, Webster KE, Sprent J, Christ D.

Nat Commun. 2017 May 12;8:15373. doi: 10.1038/ncomms15373.


Influence of nanoparticle-mediated transfection on proliferation of primary immune cells in vitro and in vivo.

Przybylski S, Gasch M, Marschner A, Ebert M, Ewe A, Helmig G, Hilger N, Fricke S, Rudzok S, Aigner A, Burkhardt J.

PLoS One. 2017 May 2;12(5):e0176517. doi: 10.1371/journal.pone.0176517. eCollection 2017.


Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches.

Kamta J, Chaar M, Ande A, Altomare DA, Ait-Oudhia S.

Front Oncol. 2017 Apr 18;7:64. doi: 10.3389/fonc.2017.00064. eCollection 2017. Review.


Cancer Immunotherapy: Whence and Whither.

Stambrook PJ, Maher J, Farzaneh F.

Mol Cancer Res. 2017 Jun;15(6):635-650. doi: 10.1158/1541-7786.MCR-16-0427. Epub 2017 Mar 29. Review.


Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?

Amin A, White RL.

J Kidney Cancer VHL. 2014 Nov 23;1(7):74-83. doi: 10.15586/jkcvhl.2014.18. eCollection 2014.


IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay.

Weng J, Moriarty KE, Baio FE, Chu F, Kim SD, He J, Jie Z, Xie X, Ma W, Qian J, Zhang L, Yang J, Yi Q, Neelapu SS, Kwak LW.

Oncoimmunology. 2016 Oct 7;5(12):e1237327. doi: 10.1080/2162402X.2016.1237327. eCollection 2016.


Early Subretinal Allograft Rejection Is Characterized by Innate Immune Activity.

Kennelly KP, Holmes TM, Wallace DM, O'Farrelly C, Keegan DJ.

Cell Transplant. 2017 Jun 9;26(6):983-1000. doi: 10.3727/096368917X694697. Epub 2017 Jan 20.


T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

Wang Z, Li B, Ren Y, Ye Z.

Front Immunol. 2016 Sep 14;7:353. doi: 10.3389/fimmu.2016.00353. eCollection 2016. Review.


Adjuvants for peptide-based cancer vaccines.

Khong H, Overwijk WW.

J Immunother Cancer. 2016 Sep 20;4:56. doi: 10.1186/s40425-016-0160-y. eCollection 2016. Review.


ICOS Co-Stimulation: Friend or Foe?

Wikenheiser DJ, Stumhofer JS.

Front Immunol. 2016 Aug 10;7:304. doi: 10.3389/fimmu.2016.00304. eCollection 2016. Review.


Role of IL-2 in cancer immunotherapy.

Jiang T, Zhou C, Ren S.

Oncoimmunology. 2016 Apr 25;5(6):e1163462. doi: 10.1080/2162402X.2016.1163462. eCollection 2016 Jun. Review.


A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.

Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT.

Oncotarget. 2016 Sep 27;7(39):64390-64399. doi: 10.18632/oncotarget.10453.


Quantitative Contribution of IL2Rγ to the Dynamic Formation of IL2-IL2R Complexes.

Ponce LF, García-Martínez K, León K.

PLoS One. 2016 May 19;11(5):e0155684. doi: 10.1371/journal.pone.0155684. eCollection 2016.


CD275-Independent IL-17-Producing T Follicular Helper-like Cells in Lymphopenic Autoimmune-Prone Mice.

Smith C, Buhlmann JE, Wang X, Bartlett A, Lim B, Barrington RA.

J Immunol. 2016 Jun 15;196(12):4935-46. doi: 10.4049/jimmunol.1402193. Epub 2016 May 16.


Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.

Mandal R, Chan TA.

Cancer Discov. 2016 Jul;6(7):703-13. doi: 10.1158/2159-8290.CD-16-0146. Epub 2016 Apr 22. Review.


Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes.

Pham MN, von Herrath MG, Vela JL.

Front Immunol. 2016 Jan 11;6:651. doi: 10.3389/fimmu.2015.00651. eCollection 2015. Review.


IL-2/α-IL-2 Complex Treatment Cannot Be Substituted for the Adoptive Transfer of Regulatory T cells to Promote Bone Marrow Engraftment.

Mahr B, Unger L, Hock K, Pilat N, Baranyi U, Schwarz C, Maschke S, Farkas AM, Wekerle T.

PLoS One. 2016 Jan 5;11(1):e0146245. doi: 10.1371/journal.pone.0146245. eCollection 2016.

Supplemental Content

Support Center